At least 81 U.S. healthcare workers have contracted laboratory-confirmed cases of the novel H1N1 influenza virus and about half caught the bug on the job, the Centers for Disease Control and Prevention said Thursday.
The finding is worrisome because it suggests that hospitals and workers are not taking sufficient preventive measures to limit the spread of the virus.
Meanwhile, the CDC has stated:
Virologists received a bit of a scare this week when researchers at the Adolfo Lutz Bacteriological Institute in Sao Paulo, Brazil, reported that they had isolated a mutated H1N1 virus from a patient who had recovered.
But academic researchers and scientists at the CDC discounted the report, noting that there were no changes in the portions of the virus that would alter its ability to spread or its pathogenicity.
But wait, what are investors concerned about?
Containing The Mutating H1N1 Flu Virus: (NASDAQ:NVAX), (NYSE:AZN), (NYSE:NVS), (NYSE:SNY)
BioMedReports.com, the news portal covering the biomedical sector that delivers financial and investment intelligence to a community of highly informed investors has initiated a special report on news of the mutation of the H1N1 Flu virus and it examines which companies may be able to help.
The new strain of influenza appears to have mutated to become more infectious for humans, the online edition of science magazine Nature reported, referencing research by a team including Professor Yoshihiro Kawaoka of Tokyo University's Institute of Medical Science.
Dr. Kawaoka is very well known for the breakthrough of artificially-made influenza, as well as for remodeling ebola virus into a safe one which increases only in particular cells.
Although the new strain of Influenza identified this year that spread widely from Mexico seems to have converged, the next one is said to be coming in already without a sound; the mutant virus.
Companies with both existing and new products for treating the swine flu are covered in the special report.
Novavax, Inc. (NASDAQ:NVAX)
AstraZeneca PLC (NYSE:AZN)
Novartis AG (NYSE:NVS)
Sanofi-Aventis SA (NYSE:SNY)
I posted the story on the mutation here.
And I posted about GlaxoSmithKline and their delay on a H1N1 vaccine even though they had the first contracts to supply the vaccine.
Now they are a few months from distribution of a vaccine, while labs listed above will be distributing a H1N1 vaccine in July. This would indicate Glaxo IS working on a new strain.
The fact that the H1N1 virus is mutating, but the CDC is denying that it is and the World Health Organization has denied that the H1N1 virus was man-made, when stories now show that its origin came from Russian scientists should make one pause and ask why are these organizations not telling the truth.